Research
Related scientific papers
Cuzick, J., I. Sestak, M. Baum, et al.,
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Lancet Oncol, 2010.
Sestak, I., W. Distler, J.F. Forbes, et al.,
Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial.
J Clin Oncol, 2010. 28(21): p. 3411-5.
Eastell, R., J. Adams, G. Clack, et al.,
Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial.
Ann Oncol.
Sestak I, Sapunar F, Cuzick J. (2009).
Aromatase Inhibitor-Induced Carpal Tunnel Syndrome: Results From the ATAC Trial.
J Clin Oncol. .
Cuzick J (2008).
Hormone replacement therapy and the risk of breast cancer.
European Journal of Cancer 44: 2344-2349.
Sestak I, Cuzick J, Sapunar F, Eastell R, Forbes J.F., Bianco A.R., Buzdar A.U., ATAC Trialists' Group (2008).
Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.
Lancet Oncol. 9(9): 866-72.
Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H; Holli K, Howell A (2007).
Long-Term Results of Tamoxifen Prophylaxis for Breast Cancer – 96-Month Follow-up of the Randomized IBIS-I Trial.
JNCI 99: 272-282.
Norman F. Boyd, M.D., et al. (2007).
Mammographic Density and the Risk and Detection of Breast Cancer.
NEJM 356:227-236
Trevor J. Powles, Sue Ashley, Alwynne Tidy, Ian E. Smith, Mitch Dowsett, (2007).
Twenty-Year Follow-up of the Royal Marsden Randomized, Double-Blinded Tamoxifen Breast Cancer Prevention Trial.
JNCI 99(4):283-290
The ATAC Trialists’ Group: Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G, Houghton J, Locker GY, Nabholtz JM (2006).
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.
Lancet Oncol. Aug; 7(8):633-43.
Victor G. Vogel, MD, et al. (2006).
Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial
JAMA 295:2727-2741
Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS; ATAC Trialists' Group (2005).
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer.
Lancet 365: 60-2.
